• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial.
 

Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial.

Options
  • Details
  • Files
BORIS DOI
10.48350/181793
Publisher DOI
10.1182/blood.2022019160
PubMed ID
36898087
Date of Publication
2023-05-25
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Contributor(s)
Ngai, Lok Lam
Hanekamp, Diana
Janssen, Fleur
Carbaat-Ham, Jannemieke
Hofland, Maaike A M
Fayed, Mona M H E
Kelder, Angèle
Oudshoorn-van Marsbergen, Laura
Scholten, Willemijn J
Snel, Alexander N
Bachas, Costa
Tettero, Jesse M
Breems, Dimitri A
Fischer, Thomas
Gjertsen, Bjorn T
Griskevicius, Laimonas
Juliusson, Gunnar
van de Loosdrecht, Arjan A
Maertens, Johan A
Manz, Markus G
Pabst, Thomas Niklaus
Universitätsklinik für Medizinische Onkologie
Passweg, Jakob R
Porkka, Kimmo
Valk, Peter J M
Gradowska, Patrycja
Löwenberg, Bob
de Leeuw, David C
Janssen, Jeroen J W M
Ossenkoppele, Gert J
Cloos, Jacqueline
Additional Credits
Universitätsklinik für Medizinische Onkologie
Series
Blood
Publisher
American Society of Hematology
ISSN
1528-0020
Access(Rights)
restricted
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo